Literature DB >> 29282571

Controversies of the classification of TMA and the terminology of aHUS.

Hideki Kato1, Masaomi Nangaku2, Hirokazu Okada3, Shoji Kagami4.   

Abstract

Mesh：

Year:  2017        PMID： 29282571     DOI： 10.1007/s10157-017-1524-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  4 in total

1.  Clinical guides for atypical hemolytic uremic syndrome in Japan.

Authors:  Hideki Kato; Masaomi Nangaku; Hiroshi Hataya; Toshihiro Sawai; Akira Ashida; Rika Fujimaru; Yoshihiko Hidaka; Shinya Kaname; Shoichi Maruyama; Takashi Yasuda; Yoko Yoshida; Shuichi Ito; Motoshi Hattori; Yoshitaka Miyakawa; Yoshihiro Fujimura; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2016-08       Impact factor: 2.801

2.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

3.  Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society.

Authors:  Toshihiro Sawai; Masaomi Nangaku; Akira Ashida; Rika Fujimaru; Hiroshi Hataya; Yoshihiko Hidaka; Shinya Kaname; Hirokazu Okada; Waichi Sato; Takashi Yasuda; Yoko Yoshida; Yoshihiro Fujimura; Motoshi Hattori; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2014-02       Impact factor: 2.801

4.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Timothy H J Goodship; H Terence Cook; Fadi Fakhouri; Fernando C Fervenza; Véronique Frémeaux-Bacchi; David Kavanagh; Carla M Nester; Marina Noris; Matthew C Pickering; Santiago Rodríguez de Córdoba; Lubka T Roumenina; Sanjeev Sethi; Richard J H Smith
Journal:  Kidney Int       Date:  2016-12-16       Impact factor: 10.612
  4 in total
  2 in total

1.  Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

Authors:  Gema Ariceta
Journal:  Pediatr Nephrol       Date:  2019-01-28       Impact factor: 3.714

2.  Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report.

Authors:  Daiki Saito; Eizo Watanabe; Akira Ashida; Hideki Kato; Yoko Yoshida; Masaomi Nangaku; Yasufumi Ohtsuka; Toshiyuki Miyata; Noriyuki Hattori; Shigeto Oda
Journal:  Crit Care Explor       Date:  2019-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.